Table 1.
Patients’ baseline characteristics.
| All population | Patients with type 2 diabetes mellitus (T2DM) taking metformin | Patients with type 2 diabetes mellitus (T2DM) NOT taking metformin | |
|---|---|---|---|
| Patients (n, %) | 123 | 31 (25.2%) | 26 (21.1%) |
| Median age, years | 64 | 69 | 64.5 |
| Age ≥ 70 years (n, %) | 36 (29.3%) | 15 (48.4%) | 6 (23.1%) |
| Sex (male/female) | 94/29 | 24/7 | 20/6 |
| ECOG performance status (n, %): | |||
| 0 | 36 (29.3%) | 9 (29%) | 7 (26.9%) |
| 1 | 56 (45.5%) | 14 (45.6%) | 11 (42.3%) |
| 2 | 31 (25.2%) | 8 (25.8%) | 8 (30.8%) |
| HPV positive | 6 (4.9%) | 2 (6.5%) | 1 (3.8%) |
| Smokers | 60 (48.8%) | 12 (38.7%) | 13 (50%) |
| Moderate or heavy alcohol consumption | 39 (31.7%) | 9 (29%) | 9 (34.6%) |
| Body mass index: | |||
| Obese (>30.0 kg/m2) | 4 (3.3%) | 1 (3.2%) | 1 (3.8%) |
| Overweight (≥25 kg/m2) | 9 (7.3%) | 2 (6.5%) | 2 (7.7%) |
| Normal (≥18.5 kg/m2 and < 25 kg/m2) | 47 (38.2%) | 11 (35.5%) | 10 (38.5%) |
| Underweight (<18.5 kg/m2) | 63 (51.2%) | 17 (54.8%) | 13 (50%) |
| Subsite: | |||
| Larynx | 51(41.4%) | 16 (51.6%) | 9 (34.6%) |
| Oral cavity | 20 (16.3%) | 2 (6.5%) | 5 (19.2%) |
| Oropharynx | 18 (14.6%) | 5 (16.1%) | 6 (23.1%) |
| Hypopharynx | 17 (13.8%) | 1 (3.2%) | 3 (11.5%) |
| Paranasal sinus/nasal cavity | 6 (4.9%) | 3 (9.7%) | 0 |
| Nasopharynx | 7 (22.6%) | 3 (9.7%) | 1 (3.8%) |
| Neck node, unknown primary | 4 (3.3%) | 1 (3.2%) | 2 (7.7%) |
| Disease stage: | |||
| Locoregional recurrence only | 37 (30%) | 9 (29%) | 8 (30.7%) |
| Metastatic disease only | 61 (49.6%) | 15 (48.3%) | 12 (46.2%) |
| Locoregional and metastatic disease | 25 (20.3%) | 7 (22.6%) | 6 (23.1%) |
| Received prior radiotherapy | 123 (100%) | 31 (100%) | 26 (100%) |
| Induction chemotherapy for recurrence or metastatic disease: | |||
| Cisplatin plus 5-fluoruracil | 79 (64.2%) | 20 (64.5%) | 17 (65.4%) |
| Carboplatin plus 5-fluorouracil | 44 (35.8%) | 11 (35.5%) | 9 (34.6%) |